Some of the selected genes have previously been described as survival modifiers associated with poor prognosis in patients with different types of gliomas, including: SMC4 [65], CCNB1 [66], RFC2 [67], SHOX2 [68], KIF23 [69], NEK2 [70], CRNDE [71], TGIF1 [72], GAS2L3 [73]. This evidence concerns the gene RFC2 and central nervous system cancer.